POPULARITY
Tumor Treating Fields (TTFields) is a non-invasive cancer treatment that uses alternating electric fields to disrupt the ability of cancer cells to divide. TTFields can slow down tumor growth and spread, and may help people live longer than chemotherapy alone. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses this new therapy and the Phase III LUNAR study that led to its FDA approval. Guest: Dr. Ticiana Leal is an Associate Professor and serves as Director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine.
Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists & Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment of lung cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyToday24/NovelLung).
For the free course "ChatGPT4 for Medical Writers and Editors," go to learnAMAstyle.com Visit Nascentmc.com/podcast for detailed show notes and links. Erdafitinib for Urothelial Carcinoma: The FDA has fully approved erdafitinib (Balversa) for advanced or metastatic urothelial carcinoma with FGFR3 genetic alterations in adults. This follows its initial accelerated approval and is based on the phase 3 THOR trial results, showing improved survival rates and manageable side effects. Erdafitinib reduced death risk by 36% and had a lower treatment discontinuation rate compared to chemotherapy. TTFields in NSCLC: The FDA is reviewing a premarket approval application for tumor treating fields (TTFields) combined with standard therapies for platinum-resistant non–small cell lung cancer. TTFields, first approved in 2011, disrupt cancer cell division and showed enhanced survival in NSCLC patients when combined with immune checkpoint inhibitors or docetaxel, without increasing systemic toxicities. The FDA's decision is expected in the second half of 2024. AI-Powered Device to Detect Skin Cancer: The FDA has approved the first AI-powered handheld device by DermaSensor for assisting in skin cancer detection. It uses AI-driven spectroscopy for analyzing skin lesions and is based on a study involving over 1000 patients. While not a primary screening tool, it aids in detecting melanoma and other skin cancers, especially in patients over 40, and requires further validation testing. Casgevy for Transfusion-Dependent Beta Thalassemia: The FDA has approved Casgevy (exa-cel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, for treating transfusion-dependent beta-thalassemia. This follows its approval for sickle cell disease and marks the first CRISPR gene-editing technology application for this condition. The approval came ahead of the anticipated date and follows Bluebird Bio's 2022 approval for a similar gene therapy. HyQvia for CIDP: HyQvia, an immune globulin infusion 10%, has been approved by the FDA for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. Initially approved for primary immunodeficiency, HyQvia is the only product combining immunoglobulin with hyaluronidase, allowing for monthly subcutaneous infusions. The approval is based on its demonstrated efficacy in preventing neuromuscular disability relapse. Physicians' Understanding of FDA Approval Process: A national survey reveals that many physicians have limited understanding of the FDA's drug and medical device approval processes. Only 41% of the surveyed physicians reported moderate or better comprehension of the drug approval process. Despite believing in the adequacy of FDA standards, there's a call for more rigorous post-marketing studies and enhanced education on FDA processes to avoid misconceptions and inaccurate patient advice.
Go online to PeerView.com/HHW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite all of the advances in cancer treatment, there is still a significant need for a fourth pillar of therapy that can help improve outcomes for patients across a spectrum of solid tumors, such as glioblastoma, lung cancer, and GI malignancies. In this PeerView activity, an expert faculty panel will review the latest cutting-edge data supporting the use of tumor treating fields (TTFields) and synergistic combination strategies in established and emerging solid tumor indications from CNS to thoracic malignancies and beyond. You'll gain strategies to maximize treatment adherence and quality of life, develop skills for evidence-based adverse event management, and discover life-prolonging clinical trial opportunities. Delve into the science behind the use of TTFields in the treatment of solid malignancies, the latest evidence on the efficacy and safety of this modality across approved and emerging indications, and radiation oncology–focused guidance for the safe and effective incorporation of TTFields therapy in the clinic. Upon completion of this activity, participants should be better able to: Describe the mechanistic rationale and evidence supporting the use of TTFields for the treatment of patients with CNS, thoracic, and other aggressive solid tumors; Integrate TTFields into multimodal management protocols for appropriately selected patients with CNS, thoracic, and other solid malignancies; and Devise team-based strategies designed to mitigate and manage adverse events associated with TTFields to improve outcomes in patients with difficult-to-treat cancers.
Go online to PeerView.com/HHW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite all of the advances in cancer treatment, there is still a significant need for a fourth pillar of therapy that can help improve outcomes for patients across a spectrum of solid tumors, such as glioblastoma, lung cancer, and GI malignancies. In this PeerView activity, an expert faculty panel will review the latest cutting-edge data supporting the use of tumor treating fields (TTFields) and synergistic combination strategies in established and emerging solid tumor indications from CNS to thoracic malignancies and beyond. You'll gain strategies to maximize treatment adherence and quality of life, develop skills for evidence-based adverse event management, and discover life-prolonging clinical trial opportunities. Delve into the science behind the use of TTFields in the treatment of solid malignancies, the latest evidence on the efficacy and safety of this modality across approved and emerging indications, and radiation oncology–focused guidance for the safe and effective incorporation of TTFields therapy in the clinic. Upon completion of this activity, participants should be better able to: Describe the mechanistic rationale and evidence supporting the use of TTFields for the treatment of patients with CNS, thoracic, and other aggressive solid tumors; Integrate TTFields into multimodal management protocols for appropriately selected patients with CNS, thoracic, and other solid malignancies; and Devise team-based strategies designed to mitigate and manage adverse events associated with TTFields to improve outcomes in patients with difficult-to-treat cancers.
Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma
Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma
Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma
Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma
Please visit answersincme.com/GVJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neuro-oncology discusses novel adjuvant therapies for patients with newly diagnosed glioblastoma. Upon completion of this activity, participants should be better able to: Recognize the rationale for combining tumor-treating fields (TTFields) with immunotherapy in the adjuvant treatment of newly diagnosed glioblastoma; Compare the clinical impact of emerging TTFields plus immunotherapy regimens and standard of care in the adjuvant treatment of newly diagnosed glioblastoma; and Outline strategies to personalize the selection of adjuvant therapy for patients with newly diagnosed glioblastoma.
Go online to PeerView.com/DSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For over a century, surgery, radiotherapy, and systemic therapy have served as the mainstays of cancer treatment. An opportunity to further improve survival and quality of life for patients with aggressive solid tumors has emerged with novel locoregional therapies (LRTs)—in particular, tumor treating fields (TTFields)—a state-of-the-art, noninvasive modality associated with clear efficacy benefits and minimal toxicity. Currently, TTFields is approved for newly diagnosed and recurrent glioblastoma (GBM) and resectable, previously untreated malignant pleural mesothelioma (MPM) and is being further examined across a range of solid tumors with poor prognoses. In a new activity from PeerView, expert panelists use a mix of case-based instruction and high-level presentations of evidence and guidelines to illustrate the effective use of TTFields in the treatment of patients with GBM and MPM. Throughout, the expert panelists share insights on engaging, real-world patient cases and perspectives on using TTFields as a component of multimodal therapy. Key topics include patient selection for therapy, safety management, provision of patient and caregiver education, and the potential future of TTFields as a unique LRT option in liver, pancreatic, ovarian, and gastric cancers. Upon completion of this activity, participants should be better able to: Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM); Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal, and gynecologic cancers; Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM, and other solid tumors; and Employ evidence- and team-based strategies to mitigate and manage AEs associated with novel LRTs (eg, TTFields) in patients with solid tumors.
Go online to PeerView.com/DSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For over a century, surgery, radiotherapy, and systemic therapy have served as the mainstays of cancer treatment. An opportunity to further improve survival and quality of life for patients with aggressive solid tumors has emerged with novel locoregional therapies (LRTs)—in particular, tumor treating fields (TTFields)—a state-of-the-art, noninvasive modality associated with clear efficacy benefits and minimal toxicity. Currently, TTFields is approved for newly diagnosed and recurrent glioblastoma (GBM) and resectable, previously untreated malignant pleural mesothelioma (MPM) and is being further examined across a range of solid tumors with poor prognoses. In a new activity from PeerView, expert panelists use a mix of case-based instruction and high-level presentations of evidence and guidelines to illustrate the effective use of TTFields in the treatment of patients with GBM and MPM. Throughout, the expert panelists share insights on engaging, real-world patient cases and perspectives on using TTFields as a component of multimodal therapy. Key topics include patient selection for therapy, safety management, provision of patient and caregiver education, and the potential future of TTFields as a unique LRT option in liver, pancreatic, ovarian, and gastric cancers. Upon completion of this activity, participants should be better able to: Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM); Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal, and gynecologic cancers; Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM, and other solid tumors; and Employ evidence- and team-based strategies to mitigate and manage AEs associated with novel LRTs (eg, TTFields) in patients with solid tumors.
Go online to PeerView.com/DSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For over a century, surgery, radiotherapy, and systemic therapy have served as the mainstays of cancer treatment. An opportunity to further improve survival and quality of life for patients with aggressive solid tumors has emerged with novel locoregional therapies (LRTs)—in particular, tumor treating fields (TTFields)—a state-of-the-art, noninvasive modality associated with clear efficacy benefits and minimal toxicity. Currently, TTFields is approved for newly diagnosed and recurrent glioblastoma (GBM) and resectable, previously untreated malignant pleural mesothelioma (MPM) and is being further examined across a range of solid tumors with poor prognoses. In a new activity from PeerView, expert panelists use a mix of case-based instruction and high-level presentations of evidence and guidelines to illustrate the effective use of TTFields in the treatment of patients with GBM and MPM. Throughout, the expert panelists share insights on engaging, real-world patient cases and perspectives on using TTFields as a component of multimodal therapy. Key topics include patient selection for therapy, safety management, provision of patient and caregiver education, and the potential future of TTFields as a unique LRT option in liver, pancreatic, ovarian, and gastric cancers. Upon completion of this activity, participants should be better able to: Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM); Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal, and gynecologic cancers; Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM, and other solid tumors; and Employ evidence- and team-based strategies to mitigate and manage AEs associated with novel LRTs (eg, TTFields) in patients with solid tumors.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Go online to PeerView.com/DSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For over a century, surgery, radiotherapy, and systemic therapy have served as the mainstays of cancer treatment. An opportunity to further improve survival and quality of life for patients with aggressive solid tumors has emerged with novel locoregional therapies (LRTs)—in particular, tumor treating fields (TTFields)—a state-of-the-art, noninvasive modality associated with clear efficacy benefits and minimal toxicity. Currently, TTFields is approved for newly diagnosed and recurrent glioblastoma (GBM) and resectable, previously untreated malignant pleural mesothelioma (MPM) and is being further examined across a range of solid tumors with poor prognoses. In a new activity from PeerView, expert panelists use a mix of case-based instruction and high-level presentations of evidence and guidelines to illustrate the effective use of TTFields in the treatment of patients with GBM and MPM. Throughout, the expert panelists share insights on engaging, real-world patient cases and perspectives on using TTFields as a component of multimodal therapy. Key topics include patient selection for therapy, safety management, provision of patient and caregiver education, and the potential future of TTFields as a unique LRT option in liver, pancreatic, ovarian, and gastric cancers. Upon completion of this activity, participants should be better able to: Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM); Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal, and gynecologic cancers; Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM, and other solid tumors; and Employ evidence- and team-based strategies to mitigate and manage AEs associated with novel LRTs (eg, TTFields) in patients with solid tumors.
Go online to PeerView.com/DSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For over a century, surgery, radiotherapy, and systemic therapy have served as the mainstays of cancer treatment. An opportunity to further improve survival and quality of life for patients with aggressive solid tumors has emerged with novel locoregional therapies (LRTs)—in particular, tumor treating fields (TTFields)—a state-of-the-art, noninvasive modality associated with clear efficacy benefits and minimal toxicity. Currently, TTFields is approved for newly diagnosed and recurrent glioblastoma (GBM) and resectable, previously untreated malignant pleural mesothelioma (MPM) and is being further examined across a range of solid tumors with poor prognoses. In a new activity from PeerView, expert panelists use a mix of case-based instruction and high-level presentations of evidence and guidelines to illustrate the effective use of TTFields in the treatment of patients with GBM and MPM. Throughout, the expert panelists share insights on engaging, real-world patient cases and perspectives on using TTFields as a component of multimodal therapy. Key topics include patient selection for therapy, safety management, provision of patient and caregiver education, and the potential future of TTFields as a unique LRT option in liver, pancreatic, ovarian, and gastric cancers. Upon completion of this activity, participants should be better able to: Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM); Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal, and gynecologic cancers; Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM, and other solid tumors; and Employ evidence- and team-based strategies to mitigate and manage AEs associated with novel LRTs (eg, TTFields) in patients with solid tumors.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Go online to PeerView.com/DSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For over a century, surgery, radiotherapy, and systemic therapy have served as the mainstays of cancer treatment. An opportunity to further improve survival and quality of life for patients with aggressive solid tumors has emerged with novel locoregional therapies (LRTs)—in particular, tumor treating fields (TTFields)—a state-of-the-art, noninvasive modality associated with clear efficacy benefits and minimal toxicity. Currently, TTFields is approved for newly diagnosed and recurrent glioblastoma (GBM) and resectable, previously untreated malignant pleural mesothelioma (MPM) and is being further examined across a range of solid tumors with poor prognoses. In a new activity from PeerView, expert panelists use a mix of case-based instruction and high-level presentations of evidence and guidelines to illustrate the effective use of TTFields in the treatment of patients with GBM and MPM. Throughout, the expert panelists share insights on engaging, real-world patient cases and perspectives on using TTFields as a component of multimodal therapy. Key topics include patient selection for therapy, safety management, provision of patient and caregiver education, and the potential future of TTFields as a unique LRT option in liver, pancreatic, ovarian, and gastric cancers. Upon completion of this activity, participants should be better able to: Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM); Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal, and gynecologic cancers; Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM, and other solid tumors; and Employ evidence- and team-based strategies to mitigate and manage AEs associated with novel LRTs (eg, TTFields) in patients with solid tumors.
Go online to PeerView.com/DSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For over a century, surgery, radiotherapy, and systemic therapy have served as the mainstays of cancer treatment. An opportunity to further improve survival and quality of life for patients with aggressive solid tumors has emerged with novel locoregional therapies (LRTs)—in particular, tumor treating fields (TTFields)—a state-of-the-art, noninvasive modality associated with clear efficacy benefits and minimal toxicity. Currently, TTFields is approved for newly diagnosed and recurrent glioblastoma (GBM) and resectable, previously untreated malignant pleural mesothelioma (MPM) and is being further examined across a range of solid tumors with poor prognoses. In a new activity from PeerView, expert panelists use a mix of case-based instruction and high-level presentations of evidence and guidelines to illustrate the effective use of TTFields in the treatment of patients with GBM and MPM. Throughout, the expert panelists share insights on engaging, real-world patient cases and perspectives on using TTFields as a component of multimodal therapy. Key topics include patient selection for therapy, safety management, provision of patient and caregiver education, and the potential future of TTFields as a unique LRT option in liver, pancreatic, ovarian, and gastric cancers. Upon completion of this activity, participants should be better able to: Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM); Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal, and gynecologic cancers; Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM, and other solid tumors; and Employ evidence- and team-based strategies to mitigate and manage AEs associated with novel LRTs (eg, TTFields) in patients with solid tumors.
Go online to PeerView.com/DSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For over a century, surgery, radiotherapy, and systemic therapy have served as the mainstays of cancer treatment. An opportunity to further improve survival and quality of life for patients with aggressive solid tumors has emerged with novel locoregional therapies (LRTs)—in particular, tumor treating fields (TTFields)—a state-of-the-art, noninvasive modality associated with clear efficacy benefits and minimal toxicity. Currently, TTFields is approved for newly diagnosed and recurrent glioblastoma (GBM) and resectable, previously untreated malignant pleural mesothelioma (MPM) and is being further examined across a range of solid tumors with poor prognoses. In a new activity from PeerView, expert panelists use a mix of case-based instruction and high-level presentations of evidence and guidelines to illustrate the effective use of TTFields in the treatment of patients with GBM and MPM. Throughout, the expert panelists share insights on engaging, real-world patient cases and perspectives on using TTFields as a component of multimodal therapy. Key topics include patient selection for therapy, safety management, provision of patient and caregiver education, and the potential future of TTFields as a unique LRT option in liver, pancreatic, ovarian, and gastric cancers. Upon completion of this activity, participants should be better able to: Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM); Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal, and gynecologic cancers; Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM, and other solid tumors; and Employ evidence- and team-based strategies to mitigate and manage AEs associated with novel LRTs (eg, TTFields) in patients with solid tumors.
Go online to PeerView.com/DSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For over a century, surgery, radiotherapy, and systemic therapy have served as the mainstays of cancer treatment. An opportunity to further improve survival and quality of life for patients with aggressive solid tumors has emerged with novel locoregional therapies (LRTs)—in particular, tumor treating fields (TTFields)—a state-of-the-art, noninvasive modality associated with clear efficacy benefits and minimal toxicity. Currently, TTFields is approved for newly diagnosed and recurrent glioblastoma (GBM) and resectable, previously untreated malignant pleural mesothelioma (MPM) and is being further examined across a range of solid tumors with poor prognoses. In a new activity from PeerView, expert panelists use a mix of case-based instruction and high-level presentations of evidence and guidelines to illustrate the effective use of TTFields in the treatment of patients with GBM and MPM. Throughout, the expert panelists share insights on engaging, real-world patient cases and perspectives on using TTFields as a component of multimodal therapy. Key topics include patient selection for therapy, safety management, provision of patient and caregiver education, and the potential future of TTFields as a unique LRT option in liver, pancreatic, ovarian, and gastric cancers. Upon completion of this activity, participants should be better able to: Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM); Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal, and gynecologic cancers; Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM, and other solid tumors; and Employ evidence- and team-based strategies to mitigate and manage AEs associated with novel LRTs (eg, TTFields) in patients with solid tumors.
Go online to PeerView.com/DSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For over a century, surgery, radiotherapy, and systemic therapy have served as the mainstays of cancer treatment. An opportunity to further improve survival and quality of life for patients with aggressive solid tumors has emerged with novel locoregional therapies (LRTs)—in particular, tumor treating fields (TTFields)—a state-of-the-art, noninvasive modality associated with clear efficacy benefits and minimal toxicity. Currently, TTFields is approved for newly diagnosed and recurrent glioblastoma (GBM) and resectable, previously untreated malignant pleural mesothelioma (MPM) and is being further examined across a range of solid tumors with poor prognoses. In a new activity from PeerView, expert panelists use a mix of case-based instruction and high-level presentations of evidence and guidelines to illustrate the effective use of TTFields in the treatment of patients with GBM and MPM. Throughout, the expert panelists share insights on engaging, real-world patient cases and perspectives on using TTFields as a component of multimodal therapy. Key topics include patient selection for therapy, safety management, provision of patient and caregiver education, and the potential future of TTFields as a unique LRT option in liver, pancreatic, ovarian, and gastric cancers. Upon completion of this activity, participants should be better able to: Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM); Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal, and gynecologic cancers; Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM, and other solid tumors; and Employ evidence- and team-based strategies to mitigate and manage AEs associated with novel LRTs (eg, TTFields) in patients with solid tumors.
Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tumor treating fields (TTFields)? If you are like many oncologists, gynecologists, and other clinicians involved in the treatment of patients with ovarian cancer, you may be struggling to understand which patients will benefit from treatment with these newer approaches. Join PeerView for an educational activity designed to provide busy healthcare practitioners with the information they need to use these treatments in clinical practice. Our expert faculty will provide an in-depth look at recent clinical evidence and ongoing research on PARP inhibitors, TTFields, and other novel strategies in ovarian cancer and practical guidance, drawn from their own experience, on incorporating new treatments, including through clinical trial enrollment and in combination with other modalities, into individualized treatment plans. Hear the latest on diagnostic testing for relevant biomarkers, recommendations for collaborative AE management, opportunities for clinical trial enrollment, and strategies for patient/caregiver education to help patients become well-informed participants in their own care. Upon completion of this activity, participants should be better able to: Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel treatments into the management of patients with advanced ovarian cancer, including within the context of clinical trials, considering the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage AEs related to PARP inhibitor use and other novel approaches in patients with ovarian cancer, particularly in the long-term maintenance setting.
Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tumor treating fields (TTFields)? If you are like many oncologists, gynecologists, and other clinicians involved in the treatment of patients with ovarian cancer, you may be struggling to understand which patients will benefit from treatment with these newer approaches. Join PeerView for an educational activity designed to provide busy healthcare practitioners with the information they need to use these treatments in clinical practice. Our expert faculty will provide an in-depth look at recent clinical evidence and ongoing research on PARP inhibitors, TTFields, and other novel strategies in ovarian cancer and practical guidance, drawn from their own experience, on incorporating new treatments, including through clinical trial enrollment and in combination with other modalities, into individualized treatment plans. Hear the latest on diagnostic testing for relevant biomarkers, recommendations for collaborative AE management, opportunities for clinical trial enrollment, and strategies for patient/caregiver education to help patients become well-informed participants in their own care. Upon completion of this activity, participants should be better able to: Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel treatments into the management of patients with advanced ovarian cancer, including within the context of clinical trials, considering the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage AEs related to PARP inhibitor use and other novel approaches in patients with ovarian cancer, particularly in the long-term maintenance setting.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tumor treating fields (TTFields)? If you are like many oncologists, gynecologists, and other clinicians involved in the treatment of patients with ovarian cancer, you may be struggling to understand which patients will benefit from treatment with these newer approaches. Join PeerView for an educational activity designed to provide busy healthcare practitioners with the information they need to use these treatments in clinical practice. Our expert faculty will provide an in-depth look at recent clinical evidence and ongoing research on PARP inhibitors, TTFields, and other novel strategies in ovarian cancer and practical guidance, drawn from their own experience, on incorporating new treatments, including through clinical trial enrollment and in combination with other modalities, into individualized treatment plans. Hear the latest on diagnostic testing for relevant biomarkers, recommendations for collaborative AE management, opportunities for clinical trial enrollment, and strategies for patient/caregiver education to help patients become well-informed participants in their own care. Upon completion of this activity, participants should be better able to: Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel treatments into the management of patients with advanced ovarian cancer, including within the context of clinical trials, considering the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage AEs related to PARP inhibitor use and other novel approaches in patients with ovarian cancer, particularly in the long-term maintenance setting.
Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tumor treating fields (TTFields)? If you are like many oncologists, gynecologists, and other clinicians involved in the treatment of patients with ovarian cancer, you may be struggling to understand which patients will benefit from treatment with these newer approaches. Join PeerView for an educational activity designed to provide busy healthcare practitioners with the information they need to use these treatments in clinical practice. Our expert faculty will provide an in-depth look at recent clinical evidence and ongoing research on PARP inhibitors, TTFields, and other novel strategies in ovarian cancer and practical guidance, drawn from their own experience, on incorporating new treatments, including through clinical trial enrollment and in combination with other modalities, into individualized treatment plans. Hear the latest on diagnostic testing for relevant biomarkers, recommendations for collaborative AE management, opportunities for clinical trial enrollment, and strategies for patient/caregiver education to help patients become well-informed participants in their own care. Upon completion of this activity, participants should be better able to: Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel treatments into the management of patients with advanced ovarian cancer, including within the context of clinical trials, considering the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage AEs related to PARP inhibitor use and other novel approaches in patients with ovarian cancer, particularly in the long-term maintenance setting.
Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tumor treating fields (TTFields)? If you are like many oncologists, gynecologists, and other clinicians involved in the treatment of patients with ovarian cancer, you may be struggling to understand which patients will benefit from treatment with these newer approaches. Join PeerView for an educational activity designed to provide busy healthcare practitioners with the information they need to use these treatments in clinical practice. Our expert faculty will provide an in-depth look at recent clinical evidence and ongoing research on PARP inhibitors, TTFields, and other novel strategies in ovarian cancer and practical guidance, drawn from their own experience, on incorporating new treatments, including through clinical trial enrollment and in combination with other modalities, into individualized treatment plans. Hear the latest on diagnostic testing for relevant biomarkers, recommendations for collaborative AE management, opportunities for clinical trial enrollment, and strategies for patient/caregiver education to help patients become well-informed participants in their own care. Upon completion of this activity, participants should be better able to: Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel treatments into the management of patients with advanced ovarian cancer, including within the context of clinical trials, considering the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage AEs related to PARP inhibitor use and other novel approaches in patients with ovarian cancer, particularly in the long-term maintenance setting.
Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tumor treating fields (TTFields)? If you are like many oncologists, gynecologists, and other clinicians involved in the treatment of patients with ovarian cancer, you may be struggling to understand which patients will benefit from treatment with these newer approaches. Join PeerView for an educational activity designed to provide busy healthcare practitioners with the information they need to use these treatments in clinical practice. Our expert faculty will provide an in-depth look at recent clinical evidence and ongoing research on PARP inhibitors, TTFields, and other novel strategies in ovarian cancer and practical guidance, drawn from their own experience, on incorporating new treatments, including through clinical trial enrollment and in combination with other modalities, into individualized treatment plans. Hear the latest on diagnostic testing for relevant biomarkers, recommendations for collaborative AE management, opportunities for clinical trial enrollment, and strategies for patient/caregiver education to help patients become well-informed participants in their own care. Upon completion of this activity, participants should be better able to: Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel treatments into the management of patients with advanced ovarian cancer, including within the context of clinical trials, considering the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage AEs related to PARP inhibitor use and other novel approaches in patients with ovarian cancer, particularly in the long-term maintenance setting.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tumor treating fields (TTFields)? If you are like many oncologists, gynecologists, and other clinicians involved in the treatment of patients with ovarian cancer, you may be struggling to understand which patients will benefit from treatment with these newer approaches. Join PeerView for an educational activity designed to provide busy healthcare practitioners with the information they need to use these treatments in clinical practice. Our expert faculty will provide an in-depth look at recent clinical evidence and ongoing research on PARP inhibitors, TTFields, and other novel strategies in ovarian cancer and practical guidance, drawn from their own experience, on incorporating new treatments, including through clinical trial enrollment and in combination with other modalities, into individualized treatment plans. Hear the latest on diagnostic testing for relevant biomarkers, recommendations for collaborative AE management, opportunities for clinical trial enrollment, and strategies for patient/caregiver education to help patients become well-informed participants in their own care. Upon completion of this activity, participants should be better able to: Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel treatments into the management of patients with advanced ovarian cancer, including within the context of clinical trials, considering the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage AEs related to PARP inhibitor use and other novel approaches in patients with ovarian cancer, particularly in the long-term maintenance setting.
Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tumor treating fields (TTFields)? If you are like many oncologists, gynecologists, and other clinicians involved in the treatment of patients with ovarian cancer, you may be struggling to understand which patients will benefit from treatment with these newer approaches. Join PeerView for an educational activity designed to provide busy healthcare practitioners with the information they need to use these treatments in clinical practice. Our expert faculty will provide an in-depth look at recent clinical evidence and ongoing research on PARP inhibitors, TTFields, and other novel strategies in ovarian cancer and practical guidance, drawn from their own experience, on incorporating new treatments, including through clinical trial enrollment and in combination with other modalities, into individualized treatment plans. Hear the latest on diagnostic testing for relevant biomarkers, recommendations for collaborative AE management, opportunities for clinical trial enrollment, and strategies for patient/caregiver education to help patients become well-informed participants in their own care. Upon completion of this activity, participants should be better able to: Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel treatments into the management of patients with advanced ovarian cancer, including within the context of clinical trials, considering the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage AEs related to PARP inhibitor use and other novel approaches in patients with ovarian cancer, particularly in the long-term maintenance setting.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
Go online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with this complex, diverse, fast-growing, and aggressive brain tumor must be prepared to quickly create personalized management plans that incorporate several new modalities, including tumor treating fields (TTFields) and efficacious systemic therapies, as well as clinical trial–based options. In a new event from PeerView and the American Brain Tumor Association (ABTA), an expert panel will review the latest efficacy and safety data on multimodal GBM treatments, along with a clear rationale for selecting guideline-recommended treatments and strategies for incorporating these advances into clinical practice. This case-based activity has been designed to help clinicians hone their informed decision-making skills and personalize management plans and for the benefit of patients with GBM in a variety of settings. Upon completion of this CE activity, participants will be able to: Describe the biologic rationale and latest clinical evidence for the use of guideline-recommended treatment strategies, such as TTFields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent GBM, Identify patients with GBM who may benefit from participation in a clinical trial, and assess the applications of emerging approaches based on available data on their efficacy and safety, Develop personalized management plans for patients with newly diagnosed and recurrent GBM, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences.
Go online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with this complex, diverse, fast-growing, and aggressive brain tumor must be prepared to quickly create personalized management plans that incorporate several new modalities, including tumor treating fields (TTFields) and efficacious systemic therapies, as well as clinical trial–based options. In a new event from PeerView and the American Brain Tumor Association (ABTA), an expert panel will review the latest efficacy and safety data on multimodal GBM treatments, along with a clear rationale for selecting guideline-recommended treatments and strategies for incorporating these advances into clinical practice. This case-based activity has been designed to help clinicians hone their informed decision-making skills and personalize management plans and for the benefit of patients with GBM in a variety of settings. Upon completion of this CE activity, participants will be able to: Describe the biologic rationale and latest clinical evidence for the use of guideline-recommended treatment strategies, such as TTFields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent GBM, Identify patients with GBM who may benefit from participation in a clinical trial, and assess the applications of emerging approaches based on available data on their efficacy and safety, Develop personalized management plans for patients with newly diagnosed and recurrent GBM, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
Go online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with this complex, diverse, fast-growing, and aggressive brain tumor must be prepared to quickly create personalized management plans that incorporate several new modalities, including tumor treating fields (TTFields) and efficacious systemic therapies, as well as clinical trial–based options. In a new event from PeerView and the American Brain Tumor Association (ABTA), an expert panel will review the latest efficacy and safety data on multimodal GBM treatments, along with a clear rationale for selecting guideline-recommended treatments and strategies for incorporating these advances into clinical practice. This case-based activity has been designed to help clinicians hone their informed decision-making skills and personalize management plans and for the benefit of patients with GBM in a variety of settings. Upon completion of this CE activity, participants will be able to: Describe the biologic rationale and latest clinical evidence for the use of guideline-recommended treatment strategies, such as TTFields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent GBM, Identify patients with GBM who may benefit from participation in a clinical trial, and assess the applications of emerging approaches based on available data on their efficacy and safety, Develop personalized management plans for patients with newly diagnosed and recurrent GBM, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences.
Go online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with this complex, diverse, fast-growing, and aggressive brain tumor must be prepared to quickly create personalized management plans that incorporate several new modalities, including tumor treating fields (TTFields) and efficacious systemic therapies, as well as clinical trial–based options. In a new event from PeerView and the American Brain Tumor Association (ABTA), an expert panel will review the latest efficacy and safety data on multimodal GBM treatments, along with a clear rationale for selecting guideline-recommended treatments and strategies for incorporating these advances into clinical practice. This case-based activity has been designed to help clinicians hone their informed decision-making skills and personalize management plans and for the benefit of patients with GBM in a variety of settings. Upon completion of this CE activity, participants will be able to: Describe the biologic rationale and latest clinical evidence for the use of guideline-recommended treatment strategies, such as TTFields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent GBM, Identify patients with GBM who may benefit from participation in a clinical trial, and assess the applications of emerging approaches based on available data on their efficacy and safety, Develop personalized management plans for patients with newly diagnosed and recurrent GBM, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences.
Go online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with this complex, diverse, fast-growing, and aggressive brain tumor must be prepared to quickly create personalized management plans that incorporate several new modalities, including tumor treating fields (TTFields) and efficacious systemic therapies, as well as clinical trial–based options. In a new event from PeerView and the American Brain Tumor Association (ABTA), an expert panel will review the latest efficacy and safety data on multimodal GBM treatments, along with a clear rationale for selecting guideline-recommended treatments and strategies for incorporating these advances into clinical practice. This case-based activity has been designed to help clinicians hone their informed decision-making skills and personalize management plans and for the benefit of patients with GBM in a variety of settings. Upon completion of this CE activity, participants will be able to: Describe the biologic rationale and latest clinical evidence for the use of guideline-recommended treatment strategies, such as TTFields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent GBM, Identify patients with GBM who may benefit from participation in a clinical trial, and assess the applications of emerging approaches based on available data on their efficacy and safety, Develop personalized management plans for patients with newly diagnosed and recurrent GBM, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences.
Go online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with this complex, diverse, fast-growing, and aggressive brain tumor must be prepared to quickly create personalized management plans that incorporate several new modalities, including tumor treating fields (TTFields) and efficacious systemic therapies, as well as clinical trial–based options. In a new event from PeerView and the American Brain Tumor Association (ABTA), an expert panel will review the latest efficacy and safety data on multimodal GBM treatments, along with a clear rationale for selecting guideline-recommended treatments and strategies for incorporating these advances into clinical practice. This case-based activity has been designed to help clinicians hone their informed decision-making skills and personalize management plans and for the benefit of patients with GBM in a variety of settings. Upon completion of this CE activity, participants will be able to: Describe the biologic rationale and latest clinical evidence for the use of guideline-recommended treatment strategies, such as TTFields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent GBM, Identify patients with GBM who may benefit from participation in a clinical trial, and assess the applications of emerging approaches based on available data on their efficacy and safety, Develop personalized management plans for patients with newly diagnosed and recurrent GBM, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences.
Go online to PeerView.com/CHG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For clinicians managing patients with advanced ovarian cancer, the use of poly (ADP-ribose) polymerase (PARP) inhibitors and new treatment modalities such as tumor treating fields (TTFields) represents an important opportunity to provide personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors. PARP inhibitors are also being actively researched in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Already approved in glioblastoma and mesothelioma, TTFields, a new modality that targets solid tumors via alternating electric fields, is paving the way for improved outcomes in a variety of cancers, including ovarian. In an engaging new educational activity, PeerView's experts will present a series of MasterClasses featuring thorough reviews of the latest efficacy and safety data on current and emerging PARP inhibitor–based and novel therapeutic strategies for the treatment of patients with advanced ovarian cancer in a variety of settings. Drawing from their own practice, the experts will then provide guidance on using these agents—alone, in combination with other agents, and in the context of a clinical trial—with a focus on understanding the role of genetic testing, recognizing and managing adverse events, and working within a multidisciplinary care team to improve outcomes for patients. Upon completion of this accredited CE activity, participants should be better able to: Cite the mechanistic rationale and latest clinical evidence supporting the use of current and emerging PARP inhibitor–based strategies in patients with newly diagnosed and recurrent advanced ovarian cancer, Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel multimodal approaches into the management of patients with advanced ovarian cancer, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage adverse events related to the use of PARP inhibitors, particularly with long-term use such as in maintenance settings, in patients with ovarian cancer.
Go online to PeerView.com/CHG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For clinicians managing patients with advanced ovarian cancer, the use of poly (ADP-ribose) polymerase (PARP) inhibitors and new treatment modalities such as tumor treating fields (TTFields) represents an important opportunity to provide personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors. PARP inhibitors are also being actively researched in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Already approved in glioblastoma and mesothelioma, TTFields, a new modality that targets solid tumors via alternating electric fields, is paving the way for improved outcomes in a variety of cancers, including ovarian. In an engaging new educational activity, PeerView's experts will present a series of MasterClasses featuring thorough reviews of the latest efficacy and safety data on current and emerging PARP inhibitor–based and novel therapeutic strategies for the treatment of patients with advanced ovarian cancer in a variety of settings. Drawing from their own practice, the experts will then provide guidance on using these agents—alone, in combination with other agents, and in the context of a clinical trial—with a focus on understanding the role of genetic testing, recognizing and managing adverse events, and working within a multidisciplinary care team to improve outcomes for patients. Upon completion of this accredited CE activity, participants should be better able to: Cite the mechanistic rationale and latest clinical evidence supporting the use of current and emerging PARP inhibitor–based strategies in patients with newly diagnosed and recurrent advanced ovarian cancer, Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel multimodal approaches into the management of patients with advanced ovarian cancer, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage adverse events related to the use of PARP inhibitors, particularly with long-term use such as in maintenance settings, in patients with ovarian cancer.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Go online to PeerView.com/CHG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For clinicians managing patients with advanced ovarian cancer, the use of poly (ADP-ribose) polymerase (PARP) inhibitors and new treatment modalities such as tumor treating fields (TTFields) represents an important opportunity to provide personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors. PARP inhibitors are also being actively researched in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Already approved in glioblastoma and mesothelioma, TTFields, a new modality that targets solid tumors via alternating electric fields, is paving the way for improved outcomes in a variety of cancers, including ovarian. In an engaging new educational activity, PeerView's experts will present a series of MasterClasses featuring thorough reviews of the latest efficacy and safety data on current and emerging PARP inhibitor–based and novel therapeutic strategies for the treatment of patients with advanced ovarian cancer in a variety of settings. Drawing from their own practice, the experts will then provide guidance on using these agents—alone, in combination with other agents, and in the context of a clinical trial—with a focus on understanding the role of genetic testing, recognizing and managing adverse events, and working within a multidisciplinary care team to improve outcomes for patients. Upon completion of this accredited CE activity, participants should be better able to: Cite the mechanistic rationale and latest clinical evidence supporting the use of current and emerging PARP inhibitor–based strategies in patients with newly diagnosed and recurrent advanced ovarian cancer, Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel multimodal approaches into the management of patients with advanced ovarian cancer, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage adverse events related to the use of PARP inhibitors, particularly with long-term use such as in maintenance settings, in patients with ovarian cancer.
Go online to PeerView.com/CHG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For clinicians managing patients with advanced ovarian cancer, the use of poly (ADP-ribose) polymerase (PARP) inhibitors and new treatment modalities such as tumor treating fields (TTFields) represents an important opportunity to provide personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors. PARP inhibitors are also being actively researched in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Already approved in glioblastoma and mesothelioma, TTFields, a new modality that targets solid tumors via alternating electric fields, is paving the way for improved outcomes in a variety of cancers, including ovarian. In an engaging new educational activity, PeerView's experts will present a series of MasterClasses featuring thorough reviews of the latest efficacy and safety data on current and emerging PARP inhibitor–based and novel therapeutic strategies for the treatment of patients with advanced ovarian cancer in a variety of settings. Drawing from their own practice, the experts will then provide guidance on using these agents—alone, in combination with other agents, and in the context of a clinical trial—with a focus on understanding the role of genetic testing, recognizing and managing adverse events, and working within a multidisciplinary care team to improve outcomes for patients. Upon completion of this accredited CE activity, participants should be better able to: Cite the mechanistic rationale and latest clinical evidence supporting the use of current and emerging PARP inhibitor–based strategies in patients with newly diagnosed and recurrent advanced ovarian cancer, Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel multimodal approaches into the management of patients with advanced ovarian cancer, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage adverse events related to the use of PARP inhibitors, particularly with long-term use such as in maintenance settings, in patients with ovarian cancer.
Go online to PeerView.com/CHG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For clinicians managing patients with advanced ovarian cancer, the use of poly (ADP-ribose) polymerase (PARP) inhibitors and new treatment modalities such as tumor treating fields (TTFields) represents an important opportunity to provide personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors. PARP inhibitors are also being actively researched in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Already approved in glioblastoma and mesothelioma, TTFields, a new modality that targets solid tumors via alternating electric fields, is paving the way for improved outcomes in a variety of cancers, including ovarian. In an engaging new educational activity, PeerView's experts will present a series of MasterClasses featuring thorough reviews of the latest efficacy and safety data on current and emerging PARP inhibitor–based and novel therapeutic strategies for the treatment of patients with advanced ovarian cancer in a variety of settings. Drawing from their own practice, the experts will then provide guidance on using these agents—alone, in combination with other agents, and in the context of a clinical trial—with a focus on understanding the role of genetic testing, recognizing and managing adverse events, and working within a multidisciplinary care team to improve outcomes for patients. Upon completion of this accredited CE activity, participants should be better able to: Cite the mechanistic rationale and latest clinical evidence supporting the use of current and emerging PARP inhibitor–based strategies in patients with newly diagnosed and recurrent advanced ovarian cancer, Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel multimodal approaches into the management of patients with advanced ovarian cancer, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage adverse events related to the use of PARP inhibitors, particularly with long-term use such as in maintenance settings, in patients with ovarian cancer.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Go online to PeerView.com/CHG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For clinicians managing patients with advanced ovarian cancer, the use of poly (ADP-ribose) polymerase (PARP) inhibitors and new treatment modalities such as tumor treating fields (TTFields) represents an important opportunity to provide personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors. PARP inhibitors are also being actively researched in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Already approved in glioblastoma and mesothelioma, TTFields, a new modality that targets solid tumors via alternating electric fields, is paving the way for improved outcomes in a variety of cancers, including ovarian. In an engaging new educational activity, PeerView's experts will present a series of MasterClasses featuring thorough reviews of the latest efficacy and safety data on current and emerging PARP inhibitor–based and novel therapeutic strategies for the treatment of patients with advanced ovarian cancer in a variety of settings. Drawing from their own practice, the experts will then provide guidance on using these agents—alone, in combination with other agents, and in the context of a clinical trial—with a focus on understanding the role of genetic testing, recognizing and managing adverse events, and working within a multidisciplinary care team to improve outcomes for patients. Upon completion of this accredited CE activity, participants should be better able to: Cite the mechanistic rationale and latest clinical evidence supporting the use of current and emerging PARP inhibitor–based strategies in patients with newly diagnosed and recurrent advanced ovarian cancer, Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel multimodal approaches into the management of patients with advanced ovarian cancer, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage adverse events related to the use of PARP inhibitors, particularly with long-term use such as in maintenance settings, in patients with ovarian cancer.
Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma. Upon completion of this activity, participants should be better able to: Evaluate the rationale and pivotal clinical evidence on guideline-recommended treatment strategies, such as tumor treating fields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent glioblastoma, Review the latest safety and efficacy evidence and ongoing clinical trials investigating novel agents, including immune checkpoint, multikinase, gene fusion, proteasome, PARP, EGFR, and nuclear export inhibitors, for the therapeutic management of glioblastoma, Develop safe and effective personalized treatment plans, including consideration of clinical trial enrollment, for patients with newly diagnosed and recurrent glioblastoma.
Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma. Upon completion of this activity, participants should be better able to: Evaluate the rationale and pivotal clinical evidence on guideline-recommended treatment strategies, such as tumor treating fields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent glioblastoma, Review the latest safety and efficacy evidence and ongoing clinical trials investigating novel agents, including immune checkpoint, multikinase, gene fusion, proteasome, PARP, EGFR, and nuclear export inhibitors, for the therapeutic management of glioblastoma, Develop safe and effective personalized treatment plans, including consideration of clinical trial enrollment, for patients with newly diagnosed and recurrent glioblastoma.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma. Upon completion of this activity, participants should be better able to: Evaluate the rationale and pivotal clinical evidence on guideline-recommended treatment strategies, such as tumor treating fields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent glioblastoma, Review the latest safety and efficacy evidence and ongoing clinical trials investigating novel agents, including immune checkpoint, multikinase, gene fusion, proteasome, PARP, EGFR, and nuclear export inhibitors, for the therapeutic management of glioblastoma, Develop safe and effective personalized treatment plans, including consideration of clinical trial enrollment, for patients with newly diagnosed and recurrent glioblastoma.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma. Upon completion of this activity, participants should be better able to: Evaluate the rationale and pivotal clinical evidence on guideline-recommended treatment strategies, such as tumor treating fields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent glioblastoma, Review the latest safety and efficacy evidence and ongoing clinical trials investigating novel agents, including immune checkpoint, multikinase, gene fusion, proteasome, PARP, EGFR, and nuclear export inhibitors, for the therapeutic management of glioblastoma, Develop safe and effective personalized treatment plans, including consideration of clinical trial enrollment, for patients with newly diagnosed and recurrent glioblastoma.
Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma. Upon completion of this activity, participants should be better able to: Evaluate the rationale and pivotal clinical evidence on guideline-recommended treatment strategies, such as tumor treating fields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent glioblastoma, Review the latest safety and efficacy evidence and ongoing clinical trials investigating novel agents, including immune checkpoint, multikinase, gene fusion, proteasome, PARP, EGFR, and nuclear export inhibitors, for the therapeutic management of glioblastoma, Develop safe and effective personalized treatment plans, including consideration of clinical trial enrollment, for patients with newly diagnosed and recurrent glioblastoma.
Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma. Upon completion of this activity, participants should be better able to: Evaluate the rationale and pivotal clinical evidence on guideline-recommended treatment strategies, such as tumor treating fields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent glioblastoma, Review the latest safety and efficacy evidence and ongoing clinical trials investigating novel agents, including immune checkpoint, multikinase, gene fusion, proteasome, PARP, EGFR, and nuclear export inhibitors, for the therapeutic management of glioblastoma, Develop safe and effective personalized treatment plans, including consideration of clinical trial enrollment, for patients with newly diagnosed and recurrent glioblastoma.
Go online to PeerView.com/JAR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management of solid tumors. This activity will feature a review of the cutting-edge advancements in cancer devices, as well as expert insights and case discussions on the appropriate care strategies for patients being treated with new modalities like TTFields therapy. And, the interdisciplinary panel of experts will review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, NSCLC, pancreatic cancer, and other GU and GI tumors. Upon completion of this activity, participants will be able to: Describe the mechanism of action and rationale for novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, and other solid tumors, Apply team-based strategies to minimize and manage the unique AEs associated with novel therapeutic platforms, such as TTFields therapy, for solid tumors, Provide guidance to patients on new cancer treatment modalities, such as TTFields therapy, to improve adherence and optimize cancer treatment outcomes.
Go online to PeerView.com/JAR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management of solid tumors. This activity will feature a review of the cutting-edge advancements in cancer devices, as well as expert insights and case discussions on the appropriate care strategies for patients being treated with new modalities like TTFields therapy. And, the interdisciplinary panel of experts will review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, NSCLC, pancreatic cancer, and other GU and GI tumors. Upon completion of this activity, participants will be able to: Describe the mechanism of action and rationale for novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, and other solid tumors, Apply team-based strategies to minimize and manage the unique AEs associated with novel therapeutic platforms, such as TTFields therapy, for solid tumors, Provide guidance to patients on new cancer treatment modalities, such as TTFields therapy, to improve adherence and optimize cancer treatment outcomes.
Go online to PeerView.com/JAR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management of solid tumors. This activity will feature a review of the cutting-edge advancements in cancer devices, as well as expert insights and case discussions on the appropriate care strategies for patients being treated with new modalities like TTFields therapy. And, the interdisciplinary panel of experts will review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, NSCLC, pancreatic cancer, and other GU and GI tumors. Upon completion of this activity, participants will be able to: Describe the mechanism of action and rationale for novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, and other solid tumors, Apply team-based strategies to minimize and manage the unique AEs associated with novel therapeutic platforms, such as TTFields therapy, for solid tumors, Provide guidance to patients on new cancer treatment modalities, such as TTFields therapy, to improve adherence and optimize cancer treatment outcomes.
Go online to PeerView.com/JAR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management of solid tumors. This activity will feature a review of the cutting-edge advancements in cancer devices, as well as expert insights and case discussions on the appropriate care strategies for patients being treated with new modalities like TTFields therapy. And, the interdisciplinary panel of experts will review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, NSCLC, pancreatic cancer, and other GU and GI tumors. Upon completion of this activity, participants will be able to: Describe the mechanism of action and rationale for novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, and other solid tumors, Apply team-based strategies to minimize and manage the unique AEs associated with novel therapeutic platforms, such as TTFields therapy, for solid tumors, Provide guidance to patients on new cancer treatment modalities, such as TTFields therapy, to improve adherence and optimize cancer treatment outcomes.
Go online to PeerView.com/USV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the understanding of the science of pancreatic cancer have led to improved outcomes for patients with this traditionally difficult-to-treat malignancy, along with greater opportunities for oncology nurses to partner with patients and members of their cancer team to implement new standards of care. This CNE-certified activity, presented by PeerView in collaboration with Let's Win, an affiliate of the Lustgarten Foundation, will focus on effective management strategies with novel chemotherapy platforms, personalizing care with PARP and checkpoint inhibitors, and preparing for emerging multimodal approaches, such as tumor-treating fields (TTFields) therapy. Pancreatic cancer nurse expert, Gayle Jameson, will provide practical guidance on recognizing and managing adverse events associated with established and emerging treatments, counseling patients and their families on personalizing treatment plans, and addressing issues related to clinical trial enrollment. Upon completion of this activity, participants will be able to: Review the latest efficacy and safety data on available and emerging treatments for pancreatic cancer, including novel chemotherapy platforms, PARP inhibitors, targeted agents directed against molecular features/mutations, among others, Counsel patients on the clinical and potential use of novel treatments for pancreatic cancer, such as chemotherapy platforms for the metastatic setting, PARP inhibitors for the front-line maintenance setting, and the option of enrolling in clinical trials, Plan effective strategies to manage adverse events associated with established and emerging therapies for pancreatic cancer.
Go online to PeerView.com/USV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the understanding of the science of pancreatic cancer have led to improved outcomes for patients with this traditionally difficult-to-treat malignancy, along with greater opportunities for oncology nurses to partner with patients and members of their cancer team to implement new standards of care. This CNE-certified activity, presented by PeerView in collaboration with Let's Win, an affiliate of the Lustgarten Foundation, will focus on effective management strategies with novel chemotherapy platforms, personalizing care with PARP and checkpoint inhibitors, and preparing for emerging multimodal approaches, such as tumor-treating fields (TTFields) therapy. Pancreatic cancer nurse expert, Gayle Jameson, will provide practical guidance on recognizing and managing adverse events associated with established and emerging treatments, counseling patients and their families on personalizing treatment plans, and addressing issues related to clinical trial enrollment. Upon completion of this activity, participants will be able to: Review the latest efficacy and safety data on available and emerging treatments for pancreatic cancer, including novel chemotherapy platforms, PARP inhibitors, targeted agents directed against molecular features/mutations, among others, Counsel patients on the clinical and potential use of novel treatments for pancreatic cancer, such as chemotherapy platforms for the metastatic setting, PARP inhibitors for the front-line maintenance setting, and the option of enrolling in clinical trials, Plan effective strategies to manage adverse events associated with established and emerging therapies for pancreatic cancer.
Go online to PeerView.com/USV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the understanding of the science of pancreatic cancer have led to improved outcomes for patients with this traditionally difficult-to-treat malignancy, along with greater opportunities for oncology nurses to partner with patients and members of their cancer team to implement new standards of care. This CNE-certified activity, presented by PeerView in collaboration with Let's Win, an affiliate of the Lustgarten Foundation, will focus on effective management strategies with novel chemotherapy platforms, personalizing care with PARP and checkpoint inhibitors, and preparing for emerging multimodal approaches, such as tumor-treating fields (TTFields) therapy. Pancreatic cancer nurse expert, Gayle Jameson, will provide practical guidance on recognizing and managing adverse events associated with established and emerging treatments, counseling patients and their families on personalizing treatment plans, and addressing issues related to clinical trial enrollment. Upon completion of this activity, participants will be able to: Review the latest efficacy and safety data on available and emerging treatments for pancreatic cancer, including novel chemotherapy platforms, PARP inhibitors, targeted agents directed against molecular features/mutations, among others, Counsel patients on the clinical and potential use of novel treatments for pancreatic cancer, such as chemotherapy platforms for the metastatic setting, PARP inhibitors for the front-line maintenance setting, and the option of enrolling in clinical trials, Plan effective strategies to manage adverse events associated with established and emerging therapies for pancreatic cancer.
Go online to PeerView.com/USV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the understanding of the science of pancreatic cancer have led to improved outcomes for patients with this traditionally difficult-to-treat malignancy, along with greater opportunities for oncology nurses to partner with patients and members of their cancer team to implement new standards of care. This CNE-certified activity, presented by PeerView in collaboration with Let's Win, an affiliate of the Lustgarten Foundation, will focus on effective management strategies with novel chemotherapy platforms, personalizing care with PARP and checkpoint inhibitors, and preparing for emerging multimodal approaches, such as tumor-treating fields (TTFields) therapy. Pancreatic cancer nurse expert, Gayle Jameson, will provide practical guidance on recognizing and managing adverse events associated with established and emerging treatments, counseling patients and their families on personalizing treatment plans, and addressing issues related to clinical trial enrollment. Upon completion of this activity, participants will be able to: Review the latest efficacy and safety data on available and emerging treatments for pancreatic cancer, including novel chemotherapy platforms, PARP inhibitors, targeted agents directed against molecular features/mutations, among others, Counsel patients on the clinical and potential use of novel treatments for pancreatic cancer, such as chemotherapy platforms for the metastatic setting, PARP inhibitors for the front-line maintenance setting, and the option of enrolling in clinical trials, Plan effective strategies to manage adverse events associated with established and emerging therapies for pancreatic cancer.
Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials
Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials
Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials
Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials
Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials
Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials
Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials
Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials
Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials
Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials
Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials
Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials
Go online to PeerView.com/VGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in malignant pleural mesothelioma discuss tumor treating fields and novel systemic approaches to optimize patient outcomes. Upon completion of this activity, participants will be able to: Describe the rationale for use of tumor treating fields (TTFields), antiangiogenic strategies, and immunotherapeutic approaches in the management of malignant pleural mesothelioma (MPM), Discuss the latest efficacy and safety evidence on TTFields, angiokinase inhibitors, immune checkpoint inhibitors, and combination strategies in different MPM settings, Employ appropriate strategies to monitor for and manage treatment-emergent adverse events in patients with MPM receiving TTFields or other novel therapies, Recommend TTFields and other emerging systemic options appropriately, in the context of clinical trials or as they become available for daily practice, for eligible patients with MPM.
Go online to PeerView.com/VGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in malignant pleural mesothelioma discuss tumor treating fields and novel systemic approaches to optimize patient outcomes. Upon completion of this activity, participants will be able to: Describe the rationale for use of tumor treating fields (TTFields), antiangiogenic strategies, and immunotherapeutic approaches in the management of malignant pleural mesothelioma (MPM), Discuss the latest efficacy and safety evidence on TTFields, angiokinase inhibitors, immune checkpoint inhibitors, and combination strategies in different MPM settings, Employ appropriate strategies to monitor for and manage treatment-emergent adverse events in patients with MPM receiving TTFields or other novel therapies, Recommend TTFields and other emerging systemic options appropriately, in the context of clinical trials or as they become available for daily practice, for eligible patients with MPM.
Go online to PeerView.com/VGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in malignant pleural mesothelioma discuss tumor treating fields and novel systemic approaches to optimize patient outcomes. Upon completion of this activity, participants will be able to: Describe the rationale for use of tumor treating fields (TTFields), antiangiogenic strategies, and immunotherapeutic approaches in the management of malignant pleural mesothelioma (MPM), Discuss the latest efficacy and safety evidence on TTFields, angiokinase inhibitors, immune checkpoint inhibitors, and combination strategies in different MPM settings, Employ appropriate strategies to monitor for and manage treatment-emergent adverse events in patients with MPM receiving TTFields or other novel therapies, Recommend TTFields and other emerging systemic options appropriately, in the context of clinical trials or as they become available for daily practice, for eligible patients with MPM.
Go online to PeerView.com/VGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in malignant pleural mesothelioma discuss tumor treating fields and novel systemic approaches to optimize patient outcomes. Upon completion of this activity, participants will be able to: Describe the rationale for use of tumor treating fields (TTFields), antiangiogenic strategies, and immunotherapeutic approaches in the management of malignant pleural mesothelioma (MPM), Discuss the latest efficacy and safety evidence on TTFields, angiokinase inhibitors, immune checkpoint inhibitors, and combination strategies in different MPM settings, Employ appropriate strategies to monitor for and manage treatment-emergent adverse events in patients with MPM receiving TTFields or other novel therapies, Recommend TTFields and other emerging systemic options appropriately, in the context of clinical trials or as they become available for daily practice, for eligible patients with MPM.
Go online to PeerView.com/VGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in malignant pleural mesothelioma discuss tumor treating fields and novel systemic approaches to optimize patient outcomes. Upon completion of this activity, participants will be able to: Describe the rationale for use of tumor treating fields (TTFields), antiangiogenic strategies, and immunotherapeutic approaches in the management of malignant pleural mesothelioma (MPM), Discuss the latest efficacy and safety evidence on TTFields, angiokinase inhibitors, immune checkpoint inhibitors, and combination strategies in different MPM settings, Employ appropriate strategies to monitor for and manage treatment-emergent adverse events in patients with MPM receiving TTFields or other novel therapies, Recommend TTFields and other emerging systemic options appropriately, in the context of clinical trials or as they become available for daily practice, for eligible patients with MPM.
Go online to PeerView.com/VGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in malignant pleural mesothelioma discuss tumor treating fields and novel systemic approaches to optimize patient outcomes. Upon completion of this activity, participants will be able to: Describe the rationale for use of tumor treating fields (TTFields), antiangiogenic strategies, and immunotherapeutic approaches in the management of malignant pleural mesothelioma (MPM), Discuss the latest efficacy and safety evidence on TTFields, angiokinase inhibitors, immune checkpoint inhibitors, and combination strategies in different MPM settings, Employ appropriate strategies to monitor for and manage treatment-emergent adverse events in patients with MPM receiving TTFields or other novel therapies, Recommend TTFields and other emerging systemic options appropriately, in the context of clinical trials or as they become available for daily practice, for eligible patients with MPM.
Go online to PeerView.com/KGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies are revolutionizing the therapeutic management of solid tumors. This new modality of alternating electric fields therapy is FDA approved in GBM and MPM and is paving the way for improved outcomes in other solid tumors. As this previously unrecognized antimitotic therapy with a unique mode of delivery continues to be combined with conventional cancer therapies, including surgery, systemic therapy, and radiation therapy, the oncology community will benefit from understanding the practical implications in the multidisciplinary management of cancer. This activity will feature a review of the cutting-edge advancements in cancer devices, as well as expert insights and case discussions on the appropriate care strategies for patients being treated with new modalities like TTFields therapy. And, the expert panel will review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, NSCLC, pancreatic cancer, and other GI and gynecologic tumors. Upon completion of this activity, participants should be better able to: Summarize the mechanistic rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Evaluate the key safety and efficacy evidence on innovative strategies available for the therapeutic management of GBM and MPM, Review the most recent evidence and ongoing clinical trials on novel therapeutic modalities, including combining TTFields with systemic therapy, radiotherapy, or other modalities, in multiple tumor types such as lung, pancreatic, gastric, liver, and ovarian cancers, across different treatment settings, Develop strategies to effectively integrate novel technologies into the therapeutic management of patients with cancer, including through appropriate adverse event management and enrollment in clinical trials.
Go online to PeerView.com/KGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies are revolutionizing the therapeutic management of solid tumors. This new modality of alternating electric fields therapy is FDA approved in GBM and MPM and is paving the way for improved outcomes in other solid tumors. As this previously unrecognized antimitotic therapy with a unique mode of delivery continues to be combined with conventional cancer therapies, including surgery, systemic therapy, and radiation therapy, the oncology community will benefit from understanding the practical implications in the multidisciplinary management of cancer. This activity will feature a review of the cutting-edge advancements in cancer devices, as well as expert insights and case discussions on the appropriate care strategies for patients being treated with new modalities like TTFields therapy. And, the expert panel will review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, NSCLC, pancreatic cancer, and other GI and gynecologic tumors. Upon completion of this activity, participants should be better able to: Summarize the mechanistic rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Evaluate the key safety and efficacy evidence on innovative strategies available for the therapeutic management of GBM and MPM, Review the most recent evidence and ongoing clinical trials on novel therapeutic modalities, including combining TTFields with systemic therapy, radiotherapy, or other modalities, in multiple tumor types such as lung, pancreatic, gastric, liver, and ovarian cancers, across different treatment settings, Develop strategies to effectively integrate novel technologies into the therapeutic management of patients with cancer, including through appropriate adverse event management and enrollment in clinical trials.
Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.
Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.
Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.
Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.
Go online to PeerView.com/KGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies are revolutionizing the therapeutic management of solid tumors. This new modality of alternating electric fields therapy is FDA approved in GBM and MPM and is paving the way for improved outcomes in other solid tumors. As this previously unrecognized antimitotic therapy with a unique mode of delivery continues to be combined with conventional cancer therapies, including surgery, systemic therapy, and radiation therapy, the oncology community will benefit from understanding the practical implications in the multidisciplinary management of cancer. This activity will feature a review of the cutting-edge advancements in cancer devices, as well as expert insights and case discussions on the appropriate care strategies for patients being treated with new modalities like TTFields therapy. And, the expert panel will review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, NSCLC, pancreatic cancer, and other GI and gynecologic tumors. Upon completion of this activity, participants should be better able to: Summarize the mechanistic rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Evaluate the key safety and efficacy evidence on innovative strategies available for the therapeutic management of GBM and MPM, Review the most recent evidence and ongoing clinical trials on novel therapeutic modalities, including combining TTFields with systemic therapy, radiotherapy, or other modalities, in multiple tumor types such as lung, pancreatic, gastric, liver, and ovarian cancers, across different treatment settings, Develop strategies to effectively integrate novel technologies into the therapeutic management of patients with cancer, including through appropriate adverse event management and enrollment in clinical trials.
Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.
Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.
Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.
Go online to PeerView.com/KGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies are revolutionizing the therapeutic management of solid tumors. This new modality of alternating electric fields therapy is FDA approved in GBM and MPM and is paving the way for improved outcomes in other solid tumors. As this previously unrecognized antimitotic therapy with a unique mode of delivery continues to be combined with conventional cancer therapies, including surgery, systemic therapy, and radiation therapy, the oncology community will benefit from understanding the practical implications in the multidisciplinary management of cancer. This activity will feature a review of the cutting-edge advancements in cancer devices, as well as expert insights and case discussions on the appropriate care strategies for patients being treated with new modalities like TTFields therapy. And, the expert panel will review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, NSCLC, pancreatic cancer, and other GI and gynecologic tumors. Upon completion of this activity, participants should be better able to: Summarize the mechanistic rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Evaluate the key safety and efficacy evidence on innovative strategies available for the therapeutic management of GBM and MPM, Review the most recent evidence and ongoing clinical trials on novel therapeutic modalities, including combining TTFields with systemic therapy, radiotherapy, or other modalities, in multiple tumor types such as lung, pancreatic, gastric, liver, and ovarian cancers, across different treatment settings, Develop strategies to effectively integrate novel technologies into the therapeutic management of patients with cancer, including through appropriate adverse event management and enrollment in clinical trials.
Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.